Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Trop2 is a transmembrane glycoprotein involved in oncogenic signaling pathways, driving tumor development, invasion, and metastasis.
• While Trop2 is overexpressed in various malignancies, its expression and function vary across cancer types.
• The anti-Trop2 antibody-drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer.

Purpose of the Study:

• To review recent advancements in understanding Trop2 structure and function.
• To highlight Trop2's diagnostic and therapeutic potential beyond breast cancer.
• To discuss novel Trop2-targeted agents and their potential impact on cancer treatment.

Main Methods:

• Literature review of recent scientific publications on Trop2.
• Analysis of Trop2 expression patterns and functional roles in different cancer types.
• Evaluation of current and emerging Trop2-targeted therapies.

Main Results:

• Trop2 plays a significant role in tumor progression and represents a viable therapeutic target.
• The efficacy of Trop2-targeted therapies may differ across various cancer types due to expression variability.
• Several novel Trop2-targeted agents are under clinical investigation.

Conclusions:

• Trop2 holds significant promise as a diagnostic and therapeutic target for a range of cancers.
• Further research is needed to fully elucidate Trop2's role and optimize targeted therapies in diverse tumor types.
• Emerging Trop2-targeted agents are poised to reshape the treatment landscape for Trop2-positive malignancies.